Purple Biotech (PPBT) Total Debt (2015 - 2016)
Purple Biotech's (PPBT) quarterly Total Debt came in at $548000.0 in Q4 2016, little changed year-on-year from $549000.0 in Q1 2016, and little changed on a QoQ basis from $549000.0 in Q4 2015.
Purple Biotech (PPBT) Total Debt (2015 - 2016) Analysis & Trends
Purple Biotech (PPBT) has 2 years of Total Debt data on file, last reported at $548000.0 in Q4 2016.
- On a quarterly basis, Total Debt changed 0.18% year-over-year to $548000.0 in Q4 2016; TTM through Dec 2016 was $548000.0, a 0.18% change from a year earlier, with the FY2016 full-year figure at $548000.0, changed 0.18% from the prior year.
- Total Debt for Q4 2016 stood at $548000.0, roughly flat from $549000.0 in the prior quarter.
- Over the last five years, Total Debt for PPBT reached as high as $549000.0 in Q4 2015 and fell as low as $548000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.96 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 959.06 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Purple Biotech | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 548,000.00 |
| Dec 31, 2015 | 549,000.00 |